Novartis said FDA has accepted the company’s Biologics License Application filing and granted priority review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T cell therapy, in relapsed and refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
